
Eli Lilly: raises annual target ranges
(CercleFinance.com) - On its uarterly publication, Eli Lilly has raised its target range for adjusted EPS (non-GAAP) by $2.
60 to between $16.10 and $16.60, and for revenues by $3bn to between $45.4bn and $46.6bn.
For Q2, the pharmaceutical company's adjusted EPS jumped 86% y-o-y to $3.92, including $0.14 in charges for acquisitions of intellectual property rights.
At $11.3bn, sales were up 36%, driven by Mounjaro, Zepbound and Verzenio, and even 46% excluding revenues from the sale of Baqsimi rights in Q2 2023.
Pipeline progress includes the approval of Kisunla in the US for Alzheimer's disease and Jaypirca in Japan for relapsed or refractory mantle cell lymphoma, the Indianapolis-based group also highlighted.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
60 to between $16.10 and $16.60, and for revenues by $3bn to between $45.4bn and $46.6bn.
For Q2, the pharmaceutical company's adjusted EPS jumped 86% y-o-y to $3.92, including $0.14 in charges for acquisitions of intellectual property rights.
At $11.3bn, sales were up 36%, driven by Mounjaro, Zepbound and Verzenio, and even 46% excluding revenues from the sale of Baqsimi rights in Q2 2023.
Pipeline progress includes the approval of Kisunla in the US for Alzheimer's disease and Jaypirca in Japan for relapsed or refractory mantle cell lymphoma, the Indianapolis-based group also highlighted.
Copyright (c) 2024 CercleFinance.com. All rights reserved.